Programmed Cell Death (Apoptosis): Molecular Mechanisms and Implications for New Drug Discovery

A special issue of Biomolecules (ISSN 2218-273X). This special issue belongs to the section "Cellular Biochemistry".

Deadline for manuscript submissions: 30 September 2024 | Viewed by 1650

Special Issue Editors


E-Mail Website
Guest Editor
Department of Precision Medicine, University of Campania Luigi Vanvitelli, 80138 Naples, Italy
Interests: nutrition; natural products; health; bioactive compounds; free radicals; antioxidants; biochemistry of cancer; cell cycle; cancer-related biochemical pathways; cell proliferation; senescence; cancer cell death; epigenetic regulation; sirtuins and cancer; aging; oxidative stress; nitric oxide; endothelial cells; endothelial progenitor cells; angiogenesis; inflammation; cell senescence; apoptosis; atherosclerosis; endothelial dysfunction
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Department of Precision Medicine, University of Campania Luigi Vanvitelli, 80138 Naples, Italy
Interests: oxidative stress; mitochondrial dysfunction; endothelial dysfunction; tumor; cancer metabolism; nutrition; bioactive compounds; epigenetics; microRNAs; sirtuins

Special Issue Information

Dear Colleagues,

The three main characterized forms of mammalian programmed cell death are apoptosis, autophagy and necroptosis, as a regulated necrosis. Apoptosis can be activated by a death-receptor-dependent manner (extrinsic) or by mitochondrial stimulation (intrinsic) and sustained by the activation of specific cytosolic proteases, as caspases. The dysregulation of apoptosis can result in severe pathological syndromes. Although the field continues to expand and novel mechanisms orchestrating multiple cell death pathways are unveiled, such as ferroptosis, pyroptosis, parthanatos, mitotic catastrophe, etc., different critical molecular aspects of apoptotic cell death need to be examined. In addition, the pathogenesis of many diseases is closely connected with aberrantly regulated apoptotic cell death; thus, great interest has emerged in developing novel therapeutic strategies for modulating the key molecules of life/death decisions. To date, different promising approaches have progressed to clinical testing or have been approved, albeit the discovery of novel therapeutic strategies in targeting specific apoptotic modulators remains a compelling challenge.

For this Special Issue, we invite submissions of review papers or original research articles aiming to increase the knowledge on the mechanistic profile of apoptotic cell death, as well as describing the accumulating implications related to new drug discovery.

We look forward to receive your papers.

Dr. Nunzia D’Onofrio
Dr. Elisa Martino
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomolecules is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • programmed cell death
  • apoptosis
  • molecular aspects of apoptosis
  • apoptosis regulation
  • drug discovery
  • emerging therapeutic approaches

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

19 pages, 1479 KiB  
Review
Apoptosis Inhibitor 5: A Multifaceted Regulator of Cell Fate
by Hafsia Abbas, Dalia Kheira Derkaoui, Louise Jeammet, Emilie Adicéam, Jérôme Tiollier, Hélène Sicard, Thorsten Braun and Jean-Luc Poyet
Biomolecules 2024, 14(1), 136; https://doi.org/10.3390/biom14010136 - 22 Jan 2024
Viewed by 1353
Abstract
Apoptosis, or programmed cell death, is a fundamental process that maintains tissue homeostasis, eliminates damaged or infected cells, and plays a crucial role in various biological phenomena. The deregulation of apoptosis is involved in many human diseases, including cancer. One of the emerging [...] Read more.
Apoptosis, or programmed cell death, is a fundamental process that maintains tissue homeostasis, eliminates damaged or infected cells, and plays a crucial role in various biological phenomena. The deregulation of apoptosis is involved in many human diseases, including cancer. One of the emerging players in the intricate regulatory network of apoptosis is apoptosis inhibitor 5 (API5), also called AAC-11 (anti-apoptosis clone 11) or FIF (fibroblast growth factor-2 interacting factor). While it may not have yet the same level of notoriety as some other cancer-associated proteins, API5 has garnered increasing attention in the cancer field in recent years, as elevated API5 levels are often associated with aggressive tumor behavior, resistance to therapy, and poor patient prognosis. This review aims to shed light on the multifaceted functions and regulatory mechanisms of API5 in cell fate decisions as well as its interest as therapeutic target in cancer. Full article
Show Figures

Figure 1

Back to TopTop